Keywords: ADCC; antibody-dependent cell-mediated cytotoxicity; AKT; protein kinase B; ATP; adenosine triphosphate; cfDNA; circulating free DNA; CISH; chromogenic in-situ hybridization; CTC; circulating tumor cells; EGFR; epithelial growth factor receptor; EMT; epit
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: T-DM1; Trastuzumab emtansine; MCC; 4-[N-maleimidomethyl] cyclohexane-1 carboxylate; HER2; human epidermal growth receptor-2; DM-1; emtansine; NRH; nodular regenerative hyperplasia; ER; estrogen receptor; PR; progesterone recepton; TCH; docetaxel, carbopla
Keywords: Metastatic breast cancer; HER2; Trastuzumab; Pertuzumab; T-DM1; Lapatinib; Resistance; Management; Novel therapy;
Keywords: Antibodies; Immunoconjugates; Immunotoxins; Ab; antibody; Ag; antigen; ADCC; antibody-dependent cell mediated cytotoxicity; ALL; acute lymphoblastic leukemia; AML; acute myeloid leukemia; AKT; protein kinase B; APC; antigen-presenting cell; Apo2L/TRAIL; t
Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG
Keywords: ADC; antibody-drug conjugates; MMAE; monomethyl auristatin E; DAR; dhrug-to-antibody ratio; DTT; ditiothreitol; TCEP; (tris(2-carboxyethyl)phosphine; T-DM1; Trastuzumab emtansine; DM1; Mertansine; SMCC; Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-ca
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
Keywords: Brain metastases; Metastatic breast cancer; T-DM1; Trastuzumab-emtansine;
HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
Keywords: Gold nanoparticle; Trastuzumab resistance; HER2; Gastric cancer; Autophagy; Tmab; trastuzumab; HER2; human epidermal growth factor receptor 2; AuNP; gold nanoparticle; ECD; extracellular domain; ADCC; antibody-dependent cellular cytotoxicity; PTEN; phosph
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
Keywords: SYD985; T-DM1; Antibody-drug conjugate; Ovarian serous carcinoma; HER2; Ado-trastuzumab emtansine;
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
Keywords: Trastuzumab; Pertuzumab; T-DM1; HER2/neu; Epithelial ovarian carcinoma;
LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1)
Keywords: Antibody-drug conjugate; T-DM1; LC-MS/MS; Catabolites;
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study
Keywords: Breast neoplasms; Cohort studies; Palliative care; Outpatients; Real-world data; Registries; ABC; advanced breast cancer; AGO; Arbeitsgemeinschaft Gynäkologische Onkologie; Bev; bevacizumab; C; cyclophosphamid; Cap; capecitabine; Car; carboplatin; CCI; C
Systematic reviewConcurrent administration of anti-HER2 therapy and radiotherapy: Systematic review
Keywords: Irradiation; Trastuzumab; Pertuzumab; T-DM1; Lapatinib; Concomitant;
Advances in the management of HER2-positive early breast cancer
Keywords: Breast cancer; HER2; Trastuzumab; T-DM1; Neratinib; Pertuzumab; Lapatinib;
Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry
Keywords: ADC; Conjugation site analysis; T-DM1; Lysine conjugation; Signature ion fingerprinting; Normalized area quantitation;
Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Keywords: CVD; cardiovascular disease; HER2; human epidermal growth factor receptor 2; HF; heart failure; T-DM1; trastuzumab, pertuzumab, trastuzumab-emtansine; TKI; lapatinib; LV; left ventricular; ACE; angiotensin-converting enzyme (ACE) inhibitors; VEGF; vascula
Evolution of anti-HER2 therapies for cancer treatment
Keywords: HER2; Monoclonal antibodies; Trastuzumab; Pertuzumab; T-DM1; Imaging;
Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models
Keywords: Small-cell lung cancer; Chemoresistance; HER2; T-DM1; Trastuzumab emtansine;
Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series
Keywords: Breast cancer; Brain metastasis; T-DM1; Kadcyla; Adotrastuzumab; Emtansine;
Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality
Keywords: ADF; abuse deterrent formulation; API; active pharmaceutical ingredient; T-DM1; Ado-Trastuzumab Emtansine; ADC; antibody-drug conjugate; CDER; center for drug evaluation and research; CBRN/EID; chemical, biological, radiological/nuclear and emerging infec
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications
Keywords: Early breast cancer; Endocrine therapy; HER2-positive; Pertuzumab; T-DM1; Trastuzumab;
Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability
Keywords: Breast cancer; HER2; Ado-trastuzumab emtansine; T-DM1; Toxicology; Antibody-drug conjugates;
Perspectives des thérapies ciblées dans le cancer du sein métastatique
Keywords: thérapie ciblée; cancer du sein métastatique; HER-2; anti-angiogénèse; étude clinique; targeted therapy; metatstatic breast cancer; HER-2; anti-agiogenesis; clinical trial; ADCC; cytotoxicité à médiation cellulaire anticorps-dépendante; Akt; pro
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Keywords: Antibody-drug conjugate; HER2; Maytansinoid; T-DM1; Trastuzumab
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Keywords: Herceptin; T-DM1; Maytansine; Antibody–drug conjugate; Trastuzumab resistanceADCC, antibody-dependent cellular cytotoxicity; BAC, bacterial artificial chromosome; BSA, bovine serum albumin; GAHIG, goat anti-human immunoglobulin; FISH, fluorescence in situ
Clinical Updates on EGFR/HER Targeted Agents in Early-Stage Breast Cancer
Keywords: IGF-1R; Lapatinib; Monoclonal antibody; Neratinib; Pertuzumab; T-DM1; Trastuzumab